These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 32614434)

  • 1. The interplay of growth differentiation factor 15 (GDF15) expression and M2 macrophages during prostate carcinogenesis.
    Sadasivan SM; Chen Y; Gupta NS; Han X; Bobbitt KR; Chitale DA; Williamson SR; Rundle AG; Tang D; Rybicki BA
    Carcinogenesis; 2020 Aug; 41(8):1074-1082. PubMed ID: 32614434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth and differentiation factor 15 and NF-κB expression in benign prostatic biopsies and risk of subsequent prostate cancer detection.
    Rybicki BA; Sadasivan SM; Chen Y; Kravtsov O; Palangmonthip W; Arora K; Gupta NS; Williamson S; Bobbitt K; Chitale DA; Tang D; Rundle AG; Iczkowski KA
    Cancer Med; 2021 May; 10(9):3013-3025. PubMed ID: 33784024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of serum response factor expression in prostate cancer biochemical recurrence.
    Prencipe M; Fabre A; Murphy TB; Vargyas E; O'Neill A; Bjartell A; Tasken KA; Grytli HH; Svindland A; Berge V; Eri LM; Gallagher W; Watson RW
    Prostate; 2018 Jul; 78(10):724-730. PubMed ID: 29608018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Macrophage inhibitory cytokine-1 (MIC-1/GDF15) gene deletion promotes cancer growth in TRAMP prostate cancer prone mice.
    Husaini Y; Lockwood GP; Nguyen TV; Tsai VW; Mohammad MG; Russell PJ; Brown DA; Breit SN
    PLoS One; 2015; 10(2):e0115189. PubMed ID: 25695521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mass spectrometry-based assessment of prostate cancer-associated crystalloids reveals enrichment for growth and differentiation factor 15.
    Tekin B; Dasari S; Theis JD; Vrana JA; Murray DL; Oglesbee D; Thompson RH; Leibovich BC; Boorjian SA; Whaley RD; Hernandez LH; Jimenez RE; Cheville JC; Karnes RJ; Sukov WR; Gupta S
    Hum Pathol; 2023 May; 135():35-44. PubMed ID: 36906183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a distinct cluster of GDF15
    Dai C; Zhang H; Zheng Z; Li CG; Ma M; Gao H; Zhang Q; Jiang F; Cui X
    Front Immunol; 2024; 15():1309739. PubMed ID: 38655264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of GDF15 in methylseleninic acid-mediated inhibition of cell proliferation and induction of apoptosis in prostate cancer cells.
    Zhang W; Hu C; Wang X; Bai S; Cao S; Kobelski M; Lambert JR; Gu J; Zhan Y
    PLoS One; 2019; 14(9):e0222812. PubMed ID: 31539407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methylation in benign prostate and risk of disease progression in men subsequently diagnosed with prostate cancer.
    Rybicki BA; Rundle A; Kryvenko ON; Mitrache N; Do KC; Jankowski M; Chitale DA; Trudeau S; Belinsky SA; Tang D
    Int J Cancer; 2016 Jun; 138(12):2884-93. PubMed ID: 26860439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamics of expression of growth differentiation factor 15 in normal and PIN development in the mouse.
    Noorali S; Kurita T; Woolcock B; de Algara TR; Lo M; Paralkar V; Hoodless P; Vielkind J
    Differentiation; 2007 Apr; 75(4):325-36. PubMed ID: 17286605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic utility of biopsy-derived cell cycle progression score in patients with National Comprehensive Cancer Network low-risk prostate cancer undergoing radical prostatectomy: implications for treatment guidance.
    Tosoian JJ; Chappidi MR; Bishoff JT; Freedland SJ; Reid J; Brawer M; Stone S; Schlomm T; Ross AE
    BJU Int; 2017 Dec; 120(6):808-814. PubMed ID: 28481440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor infiltrating M2 macrophages could predict biochemical recurrence of localized prostate cancer after radical prostatectomy.
    Zhang Q; Xia J; Wang Y; Zhang J; Ji C; Cong R; Wang Y; Song N
    Exp Cell Res; 2019 Nov; 384(1):111588. PubMed ID: 31473209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased immunostaining for macrophage scavenger receptor is associated with poor prognosis of prostate cancer.
    Takayama H; Nonomura N; Nishimura K; Oka D; Shiba M; Nakai Y; Nakayama M; Tsujimura A; Aozasa K; Okuyama A
    BJU Int; 2009 Feb; 103(4):470-4. PubMed ID: 18778349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Akt Activation Correlates with Snail Expression and Potentially Determines the Recurrence of Prostate Cancer in Patients at Stage T2 after a Radical Prostatectomy.
    Chen WY; Hua KT; Lee WJ; Lin YW; Liu YN; Chen CL; Wen YC; Chien MH
    Int J Mol Sci; 2016 Jul; 17(8):. PubMed ID: 27455254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth differentiation factor 15 facilitates lung fibrosis by activating macrophages and fibroblasts.
    Takenouchi Y; Kitakaze K; Tsuboi K; Okamoto Y
    Exp Cell Res; 2020 Jun; 391(2):112010. PubMed ID: 32305327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Macrophage inhibitory cytokine-1 (MIC-1/GDF15) slows cancer development but increases metastases in TRAMP prostate cancer prone mice.
    Husaini Y; Qiu MR; Lockwood GP; Luo XW; Shang P; Kuffner T; Tsai VW; Jiang L; Russell PJ; Brown DA; Breit SN
    PLoS One; 2012; 7(8):e43833. PubMed ID: 22952779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular alterations in prostate carcinomas that associate with in vivo exposure to chemotherapy: identification of a cytoprotective mechanism involving growth differentiation factor 15.
    Huang CY; Beer TM; Higano CS; True LD; Vessella R; Lange PH; Garzotto M; Nelson PS
    Clin Cancer Res; 2007 Oct; 13(19):5825-33. PubMed ID: 17908975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased nuclear factor erythroid 2-related factor 2 expression predicts worse prognosis of prostate cancer patients treated with radical prostatectomy.
    Raatikainen S; Aaltomaa S; Kärjä V; Soini Y
    Hum Pathol; 2014 Nov; 45(11):2211-7. PubMed ID: 25175169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative predictive factors and further risk stratification of biochemical recurrence in clinically localized high-risk prostate cancer.
    Hamada R; Nakashima J; Ohori M; Ohno Y; Komori O; Yoshioka K; Tachibana M
    Int J Clin Oncol; 2016 Jun; 21(3):595-600. PubMed ID: 26585896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PSCA, Cox-2, and Ki-67 are independent, predictive markers of biochemical recurrence in clinically localized prostate cancer: a retrospective study.
    Kim SH; Park WS; Park BR; Joo J; Joung JY; Seo HK; Chung J; Lee KH
    Asian J Androl; 2017; 19(4):458-462. PubMed ID: 27232854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of the EpCAM expression on biochemical recurrence-free survival in clinically localized prostate cancer.
    Benko G; Spajić B; Krušlin B; Tomas D
    Urol Oncol; 2013 May; 31(4):468-74. PubMed ID: 21514185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.